After years of careful preclinical foundation work, Nimbus Therapeutics has added another marquee name to its Big Pharma-heavy list of backers and put together a $43 million B round that will put its computer-driven drug design technology to the clinical test in one of the hottest fields in biotech.
Our annual Fierce 15 report on a top class of up-and-coming private biotechs came out today and I wanted to highlight the responses from many of the companies which are on the list. Read more | Check out this year's report
Last year when Ryan McBride and I were sorting through our short list of candidates, we both felt that Seaside Therapeutics deserved a spot on the list. The small company had raised a considerable...
Shire has nailed down another deal to fuel its growing rare disease unit. The pharma group has tapped the Cambridge, MA-based startup Nimbus Discovery, which will use its computational approach to find small-molecule drugs for rare genetic diseases known as lysosomal storage disorders.
Dan Lynch, the former CEO and financial chief of ImClone Systems (acquired by Eli Lilly), has taken the executive chairman job at the Cambridge, MA-based biotech startup Nimbus Discovery.
As biotechs face monumental funding challenges and a stingy IPO market, young companies are investing in business models that have the potential to maximize the value of their drug candidates.
A little biotech start-up in Cambridge, MA with big plans for computational drug discovery work has lined up a $24 million A round with the help of some high-profile investors, including Microsoft's
Bill Gates has invested a small part of his personal fortune and professional reputation in a Cambridge, MA-based startup that is promising to use cutting-edge computational technology to identify